The American Journal of Managed Care2d
FDA Approves Guselkumab for Adult Patients With Crohn Disease
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...
PharmiWeb4d
Mesotherapy Market Outlook to Exceed USD 1.4 Billion by 2034 at 5.2% CAGR - Exclusive Report by Transparency Market Research Inc.
The global mesotherapy market, valued at US$ 801.2 Mn in 2023, is set to experience steady growth over the next decade. With ...
Face2Face Africa5d
White model who injected skin to become Black reveals plans to ‘move to Africa’
A white model who had a subcutaneous injection to become black has revealed her intentions of moving to Africa in the next ...
Endpoints News6d
As­traZeneca taps Al­teogen in deal worth more than $1.3B to make sub­cu­ta­neous can­cer drugs
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple ...
Fierce Pharma6d
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...